FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Titan Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Titan Pharmaceuticals, Inc. (TTNP) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTTNP
TTNP
Titan Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TTNP
Home🔹Stocks🔹Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc.

TTNP•NASDAQ

Titan Pharmaceuticals, Inc.

TTNP•NASDAQ
Market cap
$3.11M
Sentiment

Your view on TTNP

Mkt Cap
$3.11M
Sentiment
Your view
TTNP
Titan Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TTNP
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Titan Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Weei Jye Chay
Headquarters
400 Oyster Point Boulevard, New York City, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Weei Jye Chay
Headquarters
400 Oyster Point Boulevard, New York City, CA, US
Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News